Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate [version 2; peer review: 2 approved]
Background: This study aims to determine the factors affecting HBV DNA suppression in chronic hepatitis B patients with tenofovir disoproxil fumarate (TDF). Methods: A case-control was carried out from October 2021 to August 2022 on 182 chronic hepatitis B patients who had TDF therapy regularly for...
Main Authors: | Putri Chairani Eyanoer, Masrul Lubis, Mustafa Mahmud Amin, Fauzi Yusuf, Tri Widyawati, Muhammad Rusda, Dharma Lindarto, Jelita Siregar, Imelda Rey, Darmadi Darmadi |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2023-08-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | https://f1000research.com/articles/11-1521/v2 |
Similar Items
-
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study
by: Giacomo Stroffolini, et al.
Published: (2024-02-01) -
Efficacy and safety of Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B with High Baseline Viral Load
by: Ahmed Gad Mohamed Ahmed*, et al.
Published: (2020-07-01) -
Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
by: Na Yang, et al.
Published: (2021-08-01) -
The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients
by: Selcen Korkmaz, et al.
Published: (2018-09-01) -
Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021-07-01)